According to filings with the U.S. Securities and Exchange Commission, Aardvark Therapeutics is raising up to $84,999,982.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Tien-Li Lee played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Aardvark Therapeutics
San Diego based pharmaceutical company specializing in gut brain interaction with a focus of inflammation and metabolism. Leveraging Host Adaptive Responses through Gut-Brain Signaling for the Treatment of Metabolic and Inflammatory Diseases. Aardvark is a clinical stage biopharmaceutical company focused on the development and commercialization of safe and effective small molecule therapeutics that have broad therapeutic potential. Our science is focused on bitter taste receptors (Tas2Rs). Tas2R receptors are an evolutionary well conserved class of GPCRs expressed on nearly all vertebrates and are expressed on many cells throughout the body, not just in the mouth. Among other functions, they serve as surveillance for potential toxins and their activation elicits “anti-toxin” responses which may be utilized to convey therapeutic benefits.

To learn more about Aardvark Therapeutics, visit http://www.aardvarktherapeutics.com/

Contact:
Tien-Li Lee, Chief Executive Officer
858-225-7696
https://www.linkedin.com/in/tien-lee-365759/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.